James K Carter1, Dipankar Bhattacharya1, Joshua N Borgerding2, M Isabel Fiel3, Jeremiah J Faith2,4, Scott L Friedman1. 1. Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America. 2. Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America. 3. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America. 4. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Abstract
BACKGROUND & AIM: Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) that is responsible for a growing fraction of cirrhosis and liver cancer cases worldwide. Changes in the gut microbiome have been implicated in NASH pathogenesis, but the lack of suitable murine models has been a barrier to progress. We have therefore characterized the microbiome in a well-validated murine NASH model to establish its value in modeling human disease. METHODS: The composition of intestinal microbiota was monitored in mice on a 12- or 24-week NASH protocol consisting of high fat, high sugar Western Diet (WD) plus once weekly i.p injection of low-dose CCl4. Additional mice were subjected to WD-only or CCl4-only conditions to assess the independent effect of these variables on the microbiome. RESULTS: There was substantial remodeling of the intestinal microbiome in NASH mice, characterized by declines in both species diversity and bacterial abundance. Based on changes to beta diversity, microbiota from NASH mice clustered separately from controls in principal coordinate analyses. A comparison between WD-only and CCl4-only controls with the NASH model identified WD as the primary driver of early changes to the microbiome, resulting in loss of diversity within the 1st week. A NASH signature emerged progressively at weeks 6 and 12, including, most notably, a reproducible bloom of the Firmicute order Erysipelotrichales. CONCLUSIONS: We have established a valuable model to study the role of gut microbes in NASH, enabling us to identify a new NASH gut microbiome signature.
BACKGROUND & AIM: Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) that is responsible for a growing fraction of cirrhosis and liver cancer cases worldwide. Changes in the gut microbiome have been implicated in NASH pathogenesis, but the lack of suitable murine models has been a barrier to progress. We have therefore characterized the microbiome in a well-validated murine NASH model to establish its value in modeling human disease. METHODS: The composition of intestinal microbiota was monitored in mice on a 12- or 24-week NASH protocol consisting of high fat, high sugar Western Diet (WD) plus once weekly i.p injection of low-dose CCl4. Additional mice were subjected to WD-only or CCl4-only conditions to assess the independent effect of these variables on the microbiome. RESULTS: There was substantial remodeling of the intestinal microbiome in NASH mice, characterized by declines in both species diversity and bacterial abundance. Based on changes to beta diversity, microbiota from NASH mice clustered separately from controls in principal coordinate analyses. A comparison between WD-only and CCl4-only controls with the NASH model identified WD as the primary driver of early changes to the microbiome, resulting in loss of diversity within the 1st week. A NASH signature emerged progressively at weeks 6 and 12, including, most notably, a reproducible bloom of the Firmicute order Erysipelotrichales. CONCLUSIONS: We have established a valuable model to study the role of gut microbes in NASH, enabling us to identify a new NASH gut microbiome signature.
Authors: Melanie D Spencer; Timothy J Hamp; Robert W Reid; Leslie M Fischer; Steven H Zeisel; Anthony A Fodor Journal: Gastroenterology Date: 2010-12-01 Impact factor: 22.682
Authors: Cyrielle Caussy; Anupriya Tripathi; Greg Humphrey; Shirin Bassirian; Seema Singh; Claire Faulkner; Ricki Bettencourt; Emily Rizo; Lisa Richards; Zhenjiang Z Xu; Michael R Downes; Ronald M Evans; David A Brenner; Claude B Sirlin; Rob Knight; Rohit Loomba Journal: Nat Commun Date: 2019-03-29 Impact factor: 14.919
Authors: Deemantha G Fernando; Fatima L Saravia; Samantha N Atkinson; Matthew Barron; John R Kirby; Tammy L Kindel Journal: Surg Endosc Date: 2022-06-29 Impact factor: 3.453
Authors: Melissa A Quinn; Abby E Pritchard; Joseph R Visker; Ashley C McPeek; Ruma Raghuvanshi; Christian Martin H; Austin G Wellette-Hunsucker; Eric C Leszczynski; Laura R McCabe; Karin A Pfeiffer; Robert A Quinn; David P Ferguson Journal: Am J Physiol Endocrinol Metab Date: 2022-06-06 Impact factor: 5.900
Authors: João Paulo Margiotti Dos Santos; Mariana Canevari de Maio; Monike Alves Lemes; Lucas Fornari Laurindo; Jesselina Francisco Dos Santos Haber; Marcelo Dib Bechara; Pedro Sidnei do Prado; Eduardo Costa Rauen; Fernando Costa; Barbara Cristina de Abreu Pereira; Uri Adrian Prync Flato; Ricardo de Alvares Goulart; Eduardo Federighi Baisi Chagas; Sandra Maria Barbalho Journal: Int J Mol Sci Date: 2022-01-02 Impact factor: 5.923
Authors: Dipankar Bhattacharya; Christine Becker; Benjamin Readhead; Nicolas Goossens; Jacqueline Novik; Maria Isabel Fiel; Leslie P Cousens; Björn Magnusson; Anna Backmark; Ryan Hicks; Joel T Dudley; Scott L Friedman Journal: Sci Rep Date: 2021-10-21 Impact factor: 4.379
Authors: Natalia Di Tommaso; Antonio Gasbarrini; Francesca Romana Ponziani Journal: Int J Environ Res Public Health Date: 2021-12-06 Impact factor: 3.390